183 related articles for article (PubMed ID: 38613350)
1. Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma.
Liu Q; Zhu J; Huang Z; Zhang X; Yang J
Technol Cancer Res Treat; 2024; 23():15330338241239139. PubMed ID: 38613350
[TBL] [Abstract][Full Text] [Related]
2. Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis.
Shen Z; Cai J; Tao L; Zheng J; Ye Z; Liu Y; Pan H; Wang Y; Xu J; Liang X
Cancer Gene Ther; 2023 Dec; 30(12):1663-1678. PubMed ID: 37828105
[TBL] [Abstract][Full Text] [Related]
3. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma.
Sae-Fung A; Mutirangura A; Jitkaew S
Front Immunol; 2022; 13():1051273. PubMed ID: 36733386
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer.
Zhang J; Jiang S; Gu D; Zhang W; Shen X; Qu M; Yang C; Wang Y; Gao X
Front Oncol; 2023; 13():1162653. PubMed ID: 37205181
[TBL] [Abstract][Full Text] [Related]
7. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
8. A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses in intrahepatic cholangiocarcinoma detected by single-cell RNA sequence analysis.
Ren H; Liu C; Zhang C; Wu H; Zhang J; Wang Z; Chen L; Wang H; Shao C; Zhou L
Cancer Cell Int; 2024 Mar; 24(1):92. PubMed ID: 38431620
[TBL] [Abstract][Full Text] [Related]
9. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-associated genes (CAGs) contribute to the prognosis prediction and potential therapeutic targets in hepatocellular carcinoma.
Shi X; Shi D; Yin Y; Wu Y; Chen W; Yu Y; Wang X
Cell Signal; 2024 May; 117():111072. PubMed ID: 38307306
[TBL] [Abstract][Full Text] [Related]
11. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
12. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.
Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L
Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285
[TBL] [Abstract][Full Text] [Related]
13. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification.
Chen Z; Du D; Li J; Zhang W; Shao J
Transl Cancer Res; 2024 Mar; 13(3):1268-1289. PubMed ID: 38617510
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
Song S; Zhang M; Xie P; Wang S; Wang Y
Front Immunol; 2022; 13():978909. PubMed ID: 36341328
[TBL] [Abstract][Full Text] [Related]
15. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
16. Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients.
Zhang ZJ; Huang YP; Liu ZT; Wang YX; Zhou H; Hou KX; Tang JW; Xiong L; Wen Y; Huang SF
Front Immunol; 2023; 14():1028404. PubMed ID: 36817485
[TBL] [Abstract][Full Text] [Related]
17. [Prediction of prognosis of patients with radical resection of intrahepatic cholangiocarcinoma based on single cell omics].
Chen JL; Tang Y; Qin DL; Li ZL; Tang ZH; Quan ZW
Zhonghua Wai Ke Za Zhi; 2024 Apr; 62(4):316-323. PubMed ID: 38432673
[No Abstract] [Full Text] [Related]
18. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
[TBL] [Abstract][Full Text] [Related]
19. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma.
Wang L; Yao B; Yang J; Tian Z; He J
BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684
[TBL] [Abstract][Full Text] [Related]
20. Establishment and experimental validation of a novel cuproptosis-related gene signature for prognostic implication in cholangiocarcinoma.
Chen J; Yu X; Tong H; Tang C; Tang Z
Front Oncol; 2022; 12():1054063. PubMed ID: 36568224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
